• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Frequent Tumor Burden Monitoring of Esophageal Squamous Cell Carcinoma With Circulating Tumor DNA Using Individually Designed Digital Polymerase Chain Reaction.

作者信息

Iwaya Takeshi, Endo Fumitaka, Takahashi Fumiaki, Tokino Takashi, Sasaki Yasushi, Nishizuka Satoshi S

机构信息

Department of Surgery, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan; Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.

Department of Surgery, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.

出版信息

Gastroenterology. 2021 Jan;160(1):463-465.e4. doi: 10.1053/j.gastro.2020.09.035. Epub 2020 Oct 2.

DOI:10.1053/j.gastro.2020.09.035
PMID:33011175
Abstract
摘要

相似文献

1
Frequent Tumor Burden Monitoring of Esophageal Squamous Cell Carcinoma With Circulating Tumor DNA Using Individually Designed Digital Polymerase Chain Reaction.使用个体化设计的数字聚合酶链反应通过循环肿瘤DNA对食管鳞状细胞癌进行频繁的肿瘤负荷监测
Gastroenterology. 2021 Jan;160(1):463-465.e4. doi: 10.1053/j.gastro.2020.09.035. Epub 2020 Oct 2.
2
A serum metabolomics analysis reveals a panel of screening metabolic biomarkers for esophageal squamous cell carcinoma.血清代谢组学分析揭示了一组用于食管鳞状细胞癌的筛查代谢生物标志物。
Clin Transl Med. 2021 May;11(5):e419. doi: 10.1002/ctm2.419.
3
Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence.浆细胞游离DNA中的体细胞突变是食管鳞状细胞癌复发的诊断标志物。
Oncotarget. 2016 Sep 20;7(38):62280-62291. doi: 10.18632/oncotarget.11409.
4
Blood-based biomarkers for early detection of esophageal squamous cell carcinoma.用于食管鳞状细胞癌早期检测的基于血液的生物标志物。
World J Gastroenterol. 2020 Apr 21;26(15):1708-1725. doi: 10.3748/wjg.v26.i15.1708.
5
Prediagnostic circulating inflammation biomarkers and esophageal squamous cell carcinoma: A case-cohort study in Japan.预测性循环炎症生物标志物与食管鳞癌：日本病例对照研究。
Int J Cancer. 2020 Aug 1;147(3):686-691. doi: 10.1002/ijc.32763. Epub 2019 Dec 3.
6
Early dynamics of circulating tumor DNA predict chemotherapy responses for patients with esophageal cancer.循环肿瘤 DNA 的早期动力学可预测食管癌患者的化疗反应。
Carcinogenesis. 2021 Oct 26;42(10):1239-1249. doi: 10.1093/carcin/bgab088.
7
Serum anti-TOPO48 autoantibody as a biomarker for early diagnosis and prognosis in patients with esophageal squamous cell carcinoma.血清抗TOPO48自身抗体作为食管鳞状细胞癌患者早期诊断和预后的生物标志物。
Clin Res Hepatol Gastroenterol. 2018 Jun;42(3):276-284. doi: 10.1016/j.clinre.2017.09.007. Epub 2017 Nov 21.
8
Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.局部食管癌放化疗后循环肿瘤 DNA 分析检测微小残留病灶。
Gastroenterology. 2020 Feb;158(3):494-505.e6. doi: 10.1053/j.gastro.2019.10.039. Epub 2019 Nov 9.
9
[Serum levels of miRNA-183 in patients with esophageal squamous cell carcinoma and its diagnostic value].[食管鳞状细胞癌患者血清miRNA-183水平及其诊断价值]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Oct 28;43(10):1048-1053. doi: 10.11817/j.issn.1672-7347.2018.10.002.
10
Circulating uPA as a potential prognostic biomarker for resectable esophageal squamous cell carcinoma.循环尿激酶型纤溶酶原激活剂作为可切除食管鳞状细胞癌潜在的预后生物标志物。
Medicine (Baltimore). 2019 Mar;98(9):e14717. doi: 10.1097/MD.0000000000014717.

引用本文的文献

1
Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.用于食管癌早期检测的多分析物液体活检方法：循环肿瘤DNA的作用不断扩大
Front Oncol. 2025 Aug 14;15:1622984. doi: 10.3389/fonc.2025.1622984. eCollection 2025.
2
Outcome of Conversion Surgery After Induction Therapy for Esophageal Cancer with Synchronous Para-Aortic Lymph Node Metastasis: A Multi-institutional Retrospective Study.同步主动脉旁淋巴结转移的食管癌诱导治疗后转换手术的结果：一项多机构回顾性研究
Ann Surg Oncol. 2025 Aug 20. doi: 10.1245/s10434-025-18042-w.
3
Three timepoint perioperative CEA levels are a prognostic factor for recurrence after adjuvant chemotherapy in patients with Stage II and III colorectal cancer.
围手术期三个时间点的癌胚抗原（CEA）水平是Ⅱ期和Ⅲ期结直肠癌患者辅助化疗后复发的一个预后因素。
Ann Gastroenterol Surg. 2024 Nov 19;9(3):496-504. doi: 10.1002/ags3.12886. eCollection 2025 May.
4
TP53-centric ctDNA complements PET/CT for non-invasive assessment of pathological complete response and survival after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a prospective cohort study.以TP53为中心的循环肿瘤DNA（ctDNA）辅助正电子发射断层扫描/计算机断层扫描（PET/CT）对食管鳞状细胞癌新辅助免疫化疗后的病理完全缓解和生存情况进行无创评估：一项前瞻性队列研究
Int J Surg. 2025 May 1;111(5):3256-3268. doi: 10.1097/JS9.0000000000002341.
5
Impact of Sensitive Circulating Tumor DNA Monitoring on CT Scan Intervals During Postoperative Colorectal Cancer Surveillance.敏感循环肿瘤DNA监测对术后结直肠癌监测期间CT扫描间隔的影响
Ann Surg Open. 2025 Feb 5;6(1):e549. doi: 10.1097/AS9.0000000000000549. eCollection 2025 Mar.
6
Unraveling the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma: the "omics" era.解析巴雷特食管和食管腺癌的发病机制：“组学”时代
Front Oncol. 2025 Jan 30;14:1458138. doi: 10.3389/fonc.2024.1458138. eCollection 2024.
7
Liquid Biopsy and Multidisciplinary Treatment for Esophageal Cancer.食管癌的液体活检与多学科治疗
Cancers (Basel). 2025 Jan 9;17(2):196. doi: 10.3390/cancers17020196.
8
Comprehensive Genome Profiling-Initiated Tumor-Informed Circulating Tumor DNA Monitoring for Patients With Advanced Cancer.针对晚期癌症患者，基于综合基因组分析启动的肿瘤信息指导下的循环肿瘤DNA监测
Cancer Sci. 2025 Mar;116(3):764-774. doi: 10.1111/cas.16446. Epub 2025 Jan 5.
9
Real-Time Monitoring of a Nucleic Acid Amplification Reaction Using a Mass Sensor Based on a Quartz-Crystal Microbalance.利用基于石英晶体微天平的质量传感器实时监测核酸扩增反应。
Biosensors (Basel). 2024 Mar 25;14(4):155. doi: 10.3390/bios14040155.
10
Implementable assay for monitoring minimum residual disease after radical treatment for colorectal cancer.用于监测结直肠癌根治性治疗后微小残留病灶的可实施检测方法。
Cancer Sci. 2024 Jun;115(6):1989-2001. doi: 10.1111/cas.16149. Epub 2024 Mar 26.